Almahal Mohamed A, Wan Claire, Albrecht Benjamin, Green Sarah, Babiker Ahmed
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.
IDCases. 2024 Dec 24;39:e02138. doi: 10.1016/j.idcr.2024.e02138. eCollection 2025.
Dalbavancin is a novel long acting lipoglycopeptide antibiotic with a favorable safety profile approved for treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Gram-positive organisms. Given its long half-life, a two-dose regimen can provide effective systemic therapy for up to six weeks, making it an appealing option to avoid prolonged intravenous antibiotic therapy. Herein, we report a case of a 27-year-old male who developed dalbavancin-induced fever while treating Methicillin-sensitive (MSSA) bacteremia. Despite being inconsistently reported, our case highlights fever as a possible side effect of dalbavancin therapy, and the challenging management of this adverse event given its prolonged half-life.
达巴万星是一种新型长效脂糖肽类抗生素，具有良好的安全性，已被批准用于治疗由革兰氏阳性菌引起的急性细菌性皮肤和皮肤结构感染（ABSSSI）。鉴于其半衰期长，两剂治疗方案可提供长达六周的有效全身治疗，使其成为避免长期静脉抗生素治疗的一个有吸引力的选择。在此，我们报告一例27岁男性在治疗甲氧西林敏感（MSSA）菌血症时出现达巴万星诱导的发热病例。尽管报道不一，但我们的病例突出了发热作为达巴万星治疗可能的副作用，以及鉴于其半衰期长，对这一不良事件的挑战性管理。
